ReXceptor, Inc. Report issue

For profit Phase 1
Founded: Cleveland OH United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2014
NCT02061878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

bexarotene (targretin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1